📰 Solid Tumors News
Page 31 - Solid Tumors News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Solid Tumors. Real-time updates on events, politics, business and more.
June 3, 2023
– Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC... | June 3, 2023
June 3, 2023
In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy aloneRAHWAY, N.J. & KINGSTON, Ontario--(BUSINESS WIRE)--$MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and the Ca...
June 3, 2023
– Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC... | June 7, 2023
June 3, 2023
FinancialContent fully hosted finance channel
June 3, 2023
FOSTER CITY, Calif., & HAYWARD, Calif.--(BUSINESS WIRE)--Jun 3, 2023--
June 3, 2023
– Clinically Meaningful Reduction in Risk of Progression or Death Was Observed in the Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy in First-Line, PD-L1-High NSCLC –– Objective Response Rate (ORR) Improved in Both Domvanalimab-Containing Study Arms Compared to Zimberelimab Monotherapy –– Re...
June 2, 2023
Kura Oncology (NASDAQ:KURA – Get Rating) and BeyondSpring (NASDAQ:BYSI – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability. Insider and Institutional Ownership 18.1% of BeyondSpring shares are held […]
June 1, 2023
Dublin, June 01, 2023 (GLOBE NEWSWIRE) -- The "Global T-Cell Immunotherapy Market (2023-2028) by Therapy Type, Mechanism of Action, Product Class,...
May 30, 2023
STAMFORD, Conn., May 30, 2023 -- SpringWorks Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and... | May 30, 2023
May 29, 2023
The newest report from Data Bridge Market Research, "Mineral and Bone Disorder Treatment Market" examines growth strategies, drivers, opportunities, key